Journal
CLINICAL CANCER RESEARCH
Volume 19, Issue 3, Pages 517-523Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-12-1452
Keywords
-
Categories
Funding
- National Cancer Institute [2 R01 CA116337-06A1]
- Early Detection Research Network NCI [U01 CA111275]
- Prostate Cancer Foundation Young Investigator Award
Ask authors/readers for more resources
With the rapidly developing use of next-generation sequencing technologies, there has been a surge in our knowledge of the genomic landscape of prostate cancer and a movement toward developing a molecular subclassification system for the disease. With this new understanding comes great clinical potential, both for the development of biomarkers as well as new therapeutic targets. Herein, we highlight the potential clinical use of recent discoveries and how they fit into our current paradigm. We describe the challenges that lie ahead as we move from genomic sequencing toward routine clinical practice and adopt precision cancer care for patients with prostate cancer. Clin Cancer Res; 19(3); 517-23. (C)2012 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available